

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of December 2015

Commission File Number: 001-34563

---

**CONCORD MEDICAL SERVICES HOLDINGS LIMITED**

---

18/F, Tower A, Global Trade Center  
36 North Third Ring Road East, Dongcheng District  
Beijing 100013  
People's Republic of China  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

---

---

**TABLE OF CONTENTS**

[SIGNATURE](#)  
[EX-99.1](#)

TABLE OF CONTENTS

Exhibit 99.1 – Concord Medical Declares Special Dividend

---

[Table of Contents](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

By: /s/ Jianyu Yang

Name: Jianyu Yang

Title: Chairman and Chief Executive Officer

Date: December 11, 2015

**Concord Medical Declares Special Dividend**

BEIJING, December 11, 2015 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that on December 11, 2015, its Board of Directors declared a special cash dividend of US\$0.33 per ordinary share (or US\$0.99 per American Depositary Share (“ADS”)) on the Company’s outstanding ordinary shares. The total expense for the special dividend is expected to be approximately US\$44.5 million, based on 134,799,243 ordinary shares outstanding as of September 30, 2015. Each ADS represents three ordinary shares of the Company.

The dividends are payable on or about January 30, 2016, to shareholders of record at the close of business on December 28, 2015. The ex-dividend date is expected to be on December 23, 2015.

Dr. Jianyu Yang, Chairman and CEO of the Company, commented, “We are pleased that the Board of Directors declared this special dividend, which demonstrates our strong financial position. Concord Medical is well positioned to maintain its leadership position in the fast-growing healthcare services sector and establish a leading cancer hospitals network in China. The special dividend, together with our share buyback program during the year, continues to reflect our commitment to increasing shareholder value and our confidence in the company’s future.”

**About Concord Medical**

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of September 30, 2015, the Company operated a network of 127 centers with 76 hospital partners that spanned 53 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Concord Cancer Hospital, a private hospital in Singapore in April, 2015. For more information, please see <http://ir.concordmedical.com>.

For more information, please contact:

Concord Medical Services  
Mr. Adam J. Sun (Chinese and English)  
+86 10 5957 5266  
[adam.sun@concordmedical.com](mailto:adam.sun@concordmedical.com)

---

Ms. Fang Liu (Chinese and English)  
+86 10 5903 6688 (ext. 639)  
fang.liu@concordmedical.com

ICR, Inc.  
Mr. William Zima  
+1 203-682-8233  
William.Zima@icrinc.com

SOURCE Concord Medical Services Holdings Limited